WO2014009971A3 - Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof - Google Patents

Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof Download PDF

Info

Publication number
WO2014009971A3
WO2014009971A3 PCT/IN2013/000418 IN2013000418W WO2014009971A3 WO 2014009971 A3 WO2014009971 A3 WO 2014009971A3 IN 2013000418 W IN2013000418 W IN 2013000418W WO 2014009971 A3 WO2014009971 A3 WO 2014009971A3
Authority
WO
WIPO (PCT)
Prior art keywords
purification
animal
origin
vaccine compositions
polysaccharides
Prior art date
Application number
PCT/IN2013/000418
Other languages
French (fr)
Other versions
WO2014009971A2 (en
Inventor
Krishna Murthy Ella
Venkatesan RAMASAMY
Mandalapu Gangadhara NAIDU
Annamraju Dattatreya SARMA
Original Assignee
Bharat Biotech International Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bharat Biotech International Limited filed Critical Bharat Biotech International Limited
Priority to CN201380036198.2A priority Critical patent/CN104487086B/en
Publication of WO2014009971A2 publication Critical patent/WO2014009971A2/en
Publication of WO2014009971A3 publication Critical patent/WO2014009971A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/025—Enterobacteriales, e.g. Enterobacter
    • A61K39/0275—Salmonella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Vaccine compositions and processes are disclosed for culturing the pathogenic bacteria containing virulent capsular polysaccharides in animal free culture medium, isolation, purification of polysaccharides and polysaccharide-protein conjugate. The purification of capsular polysaccharides may or may not employ alcohol for preparing immunogenic formulations. The immunogens obtained from the process of the invention were formulated and do not contain any sources of animal-origin and alcohol excipients. Also disclosed is a method for isolation, purification and conjugation of bacterial capsular polysaccharide of Haemophilus Influenza. The novel processes for purification, removal of endotoxin and formation of immuno-conjugates have also been used to generate novel compositions responsible to invoke immunogenicity against infections against Hib and prevention and treatment thereof.
PCT/IN2013/000418 2012-07-07 2013-07-08 Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof WO2014009971A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201380036198.2A CN104487086B (en) 2012-07-07 2013-07-08 Non-animal derived nonalcoholic vaccine composition and preparation method thereof

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
IN2754/CHE/2012 2012-07-07
IN2754CH2012 2012-07-07
IN2317CH2012 2012-07-11
IN2317/CHE/2012 2012-07-11

Publications (2)

Publication Number Publication Date
WO2014009971A2 WO2014009971A2 (en) 2014-01-16
WO2014009971A3 true WO2014009971A3 (en) 2014-08-28

Family

ID=49111507

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IN2013/000418 WO2014009971A2 (en) 2012-07-07 2013-07-08 Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof

Country Status (2)

Country Link
CN (1) CN104487086B (en)
WO (1) WO2014009971A2 (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015029056A1 (en) 2013-08-24 2015-03-05 Bharat Biotech International Limited A bacterial vaccine and methods for manufacture thereof
US11160855B2 (en) 2014-01-21 2021-11-02 Pfizer Inc. Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
CN104387491B (en) * 2014-11-25 2017-12-05 中国医学科学院医学生物学研究所 A kind of preparation method of Hib b
CN106146679B (en) * 2015-04-23 2019-02-01 中国医学科学院医学生物学研究所 A kind of method of purification of bacterial capsular polysaccharide
EA039487B1 (en) * 2015-07-04 2022-02-01 Бхарат Байотек Интернэшнл Лимитед Combined polysaccharide vaccine compositions and process for production of bacterial capsular polysaccharides
MX2019002489A (en) 2016-09-02 2019-10-21 Sanofi Pasteur Inc Neisseria meningitidis vaccine.
CN108690816A (en) * 2017-04-12 2018-10-23 成都生物制品研究所有限责任公司 A kind of the non-animal source culture medium and its cultural method of A groups of neisseria meningitis inflammation coccus
US20210070890A1 (en) 2019-09-06 2021-03-11 Serum Institute Of India Private Limited Method for obtaining purified bacterial polysaccharides
BR102019021510A2 (en) * 2019-10-14 2022-01-25 Instituto Butantan Process of production, recovery and purification of capsular polysaccharide polyribosyl-ribitol-phosphate (prp) and use thereof
CN112646747B (en) * 2021-01-08 2024-03-15 苏州聚微生物科技有限公司 Clostridium tetani culture medium

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000697A1 (en) * 1995-06-23 1997-01-09 Smithkline Beecham Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
WO2000056365A1 (en) * 1999-03-23 2000-09-28 Aventis Pasteur Use of trehalose for stabilising a liquid vaccine
WO2001005997A2 (en) * 1999-07-16 2001-01-25 Massachusetts Institute Of Technology Method for production of tetanus toxin using media substantially free of animal products
WO2001041800A2 (en) * 1999-12-02 2001-06-14 Chiron Corporation Compositions and methods for stabilizing biological molecules upon lyophilization
WO2005103230A2 (en) * 2004-04-22 2005-11-03 Chiron Srl Soy peptone as a nitrogen source in preparing meningococcal conjugates
WO2006042542A2 (en) * 2004-10-19 2006-04-27 Statens Serum Institut Production of tetanus, diphtheria, and pertussis toxins and toxoids using fermentation media containing no components of animal or soy origin
US20090017074A1 (en) * 2007-07-10 2009-01-15 Sanofi Pasteur Sa Culture medium for haemophilus influenzae type b
EP2277540A2 (en) * 2003-06-16 2011-01-26 GlaxoSmithKline Biologicals S.A. Polyanionic polymer adjuvants for haemophilus influenza B saccharide vaccines
WO2011148382A1 (en) * 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4220717A (en) 1977-12-22 1980-09-02 American Cyanamid Company Isolation and purification of polyribosyl ribitol phosphate from Haemophilus influenzae type b.
US4644059A (en) 1982-07-06 1987-02-17 Connaught Laboratories, Inc. Haemophilus influenzae B polysaccharide-diptheria toxoid conjugate vaccine
US5192540A (en) 1988-04-19 1993-03-09 American Cyanamid Company Haemophilus influenzae type b oxidized polysaccharide-outer membrane protein conjugate vaccine
US5045456A (en) 1989-06-12 1991-09-03 Merck & Co., Inc. Process for removing bacterial endotoxin from gram-negative polysaccharides
CA2278626C (en) 1997-01-24 2010-04-27 Schweiz. Serum- & Impfinstitut Bern Novel method for the isolation of polysaccharides
KR100385711B1 (en) * 2000-07-05 2003-05-27 녹십자백신 주식회사 The quadrivalent combination vaccine including diphtheria toxoid, tetanus toxoid, whole cell pertussis and hepatitis b surface antigen and the preparation thereof
GB0115176D0 (en) * 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
PL1664319T3 (en) 2003-09-11 2010-07-30 De Staat Der Nederlanden Vert Door De Mini Van Vws Process for producing a capsular polysaccharide for use in conjugate vaccines
CA2758323C (en) * 2004-01-29 2016-03-22 Fina Biosolutions, Llc Use of amino-oxy functional groups in the preparation of vaccines
CN102716480B (en) * 2005-04-08 2023-03-21 惠氏有限责任公司 Multivalent pneumococcal polysaccharide-protein conjugate composition
CN101378778B (en) * 2005-12-22 2013-02-06 葛兰素史密丝克莱恩生物有限公司 Vaccine comprising streptococcus pneumoniae capsular polyaccharide conjugates
KR101838938B1 (en) * 2006-03-17 2018-03-15 더 거버먼트 오브 더 유나이티드 스테이츠 오브 아메리카 에즈 레프리젠티드 바이 더 세크러테리 오브 더 디파트먼트 오브 헬스 앤드 휴먼 서비시즈 Methods for preparing complex multivalent immunogenic conjugates
CN102504042A (en) * 2011-11-17 2012-06-20 成都欧林生物科技股份有限公司 Method for removing endotoxin from bacteria capsular polysaccharide

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997000697A1 (en) * 1995-06-23 1997-01-09 Smithkline Beecham Biologicals S.A. A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
WO2000056365A1 (en) * 1999-03-23 2000-09-28 Aventis Pasteur Use of trehalose for stabilising a liquid vaccine
WO2001005997A2 (en) * 1999-07-16 2001-01-25 Massachusetts Institute Of Technology Method for production of tetanus toxin using media substantially free of animal products
WO2001041800A2 (en) * 1999-12-02 2001-06-14 Chiron Corporation Compositions and methods for stabilizing biological molecules upon lyophilization
EP2277540A2 (en) * 2003-06-16 2011-01-26 GlaxoSmithKline Biologicals S.A. Polyanionic polymer adjuvants for haemophilus influenza B saccharide vaccines
WO2005103230A2 (en) * 2004-04-22 2005-11-03 Chiron Srl Soy peptone as a nitrogen source in preparing meningococcal conjugates
WO2006042542A2 (en) * 2004-10-19 2006-04-27 Statens Serum Institut Production of tetanus, diphtheria, and pertussis toxins and toxoids using fermentation media containing no components of animal or soy origin
US20090017074A1 (en) * 2007-07-10 2009-01-15 Sanofi Pasteur Sa Culture medium for haemophilus influenzae type b
WO2011148382A1 (en) * 2010-05-28 2011-12-01 Biological E Limited An improved process for the purification of capsular polysaccharides of haemophilus influenza - b, neisseria meningitis such as serotypes a, c, y and w-135, and other similar related capsular polysaccharides produced from both gram negative and gram positive microorganisms using aluminium phosphate with alcohol.

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
HALPERIN S A ET AL: "Comparison of the Safety and Immunogenicity of an Investigational and a Licensed Quadrivalent Meningococcal Conjugate Vaccine in Children 2 to 10 Years of Age", VACCINE, ELSEVIER LTD, GB, vol. 28, no. 50, 23 November 2010 (2010-11-23), pages 7865 - 7872, XP027553548, ISSN: 0264-410X, [retrieved on 20101029] *
MICHAEL BRKER ET AL: "Biochemical and biological characteristics of cross-reacting material 197 (CRM), a non-toxic mutant of diphtheria toxin: Use as a conjugation protein in vaccines and other potential clinical applications", BIOLOGICALS, ACADEMIC PRESS LTD., LONDON, GB, vol. 39, no. 4, 24 May 2011 (2011-05-24), pages 195 - 204, XP028258631, ISSN: 1045-1056, [retrieved on 20110602], DOI: 10.1016/J.BIOLOGICALS.2011.05.004 *
NICOLA P KLEIN ET AL: "Immunogenicity and safety of a quadrivalent meningococcal conjugate vaccine administered concomitantly with measles, mumps, rubella, varicella vaccine in healthy toddlers", VACCINE, ELSEVIER LTD, GB, vol. 30, no. 26, 26 March 2012 (2012-03-26), pages 3929 - 3936, XP028488341, ISSN: 0264-410X, [retrieved on 20120403], DOI: 10.1016/J.VACCINE.2012.03.080 *

Also Published As

Publication number Publication date
CN104487086A (en) 2015-04-01
CN104487086B (en) 2019-08-30
WO2014009971A2 (en) 2014-01-16

Similar Documents

Publication Publication Date Title
WO2014009971A3 (en) Non-alcoholic vaccine compositions free from animal- origin and process for preparation thereof
PH12019501552A1 (en) Polypeptide-antigen conjugates with non-natural amino acids
PH12017501898A1 (en) Group b streptococcus polysaccharide-protein conjugates, methods for producing conjugates, immunogenic compositions comprising conjugates, and uses thereof
EA201391788A1 (en) VACCINE CONTAINING CONJUGATES OF CAPSULAR POLYSACCHARIDES STREPTOCOCCUS PNEUMONIAE
GB201101665D0 (en) Immunogenic compositions
NZ759686A (en) Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
DK2566507T3 (en) Bioconjugate vaccines with capsular gram-positive bacteria
WO2008112344A3 (en) Extracellular matrix materials as vaccine adjuvants for diseases associated with infectious pathogens or toxins
PH12015501333A1 (en) Method of making a mycoplasma vaccine
GB2455447A (en) Method of producing meningococcal meningitis vaccine for neisseria meningitidis serotypes A, C,Y and W-135
MX363409B (en) Vaccines directed against human enteroviruses.
NZ591103A (en) Methods and compositions relating to synthetic beta-1,6 glucosamine oligosaccharides
JP2010539256A5 (en)
TW200514569A (en) Vaccine composition
EP2873423A3 (en) Soluble hiv-1 envelope glycoprotein trimers
WO2009058833A3 (en) Mycoplasma bovis vaccine
AU2017261706A1 (en) Inactivating pathogens and producing highly immunogenic inactivated vaccines using a dual oxidation process
BR112015014250A2 (en) method to immunize a baby, combination vaccine and kit
WO2012106251A3 (en) Pertussis vaccine
MX2022003871A (en) Immunogenic compositions.
MX2018012270A (en) Novel pneumococcal vaccine formulations.
WO2011112906A3 (en) Novel immunogens and methods for discovery and screening thereof
AR101256A1 (en) VACCINE COMPOSITION THAT INCLUDES IPV AND CYCLODEXTRINES
MX2020000224A (en) Polysaccharide purification for vaccine production using lytic enzymes, tangential flow filtration, and multimode chromatography.
AR070368A2 (en) PROCEDURE FOR THE PREPARATION OF A VACCINE COMPOSITION THAT INCLUDES AN IMMUNOSTIMULATING AN ANTIGEN AND A METAL SALT AND USE OF SUCH COMPOSITION TO PREPARE A MEDICINAL PRODUCT. VACCINE COMPOSITION

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P5/2015

Country of ref document: AE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 13756694

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 13756694

Country of ref document: EP

Kind code of ref document: A2